Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INBX
Strong SellHot AirInhibrx Biosciences, Inc. · Healthcare · United States · $1.8B · Avg Vol: $36M/d
COMPANY DESCRIPTION
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel biologic therapeutics for oncology and orphan diseases. The company's competitive moat is derived from its proprietary single-domain antibody platform, which enables the design of multi-specific therapeutics with enhanced efficacy. It operates as a specialized biotechnology innovator in the high-value biologics space.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.3M | 1.8M | 0.2M | 1.3M | -0.0% | — | — | 36.0M | 426.5% |
| EPS | -8.10 | -16.95 | 114.01 | -9.04 | — | -8.88 | -9.26 | -8.76 | — |
| Shares | 14.2M | 14.2M | 14.5M | 14.6M | +2.4% | 14.7M | — | — | — |
| Debt | 5.0M | 210.1M | 8.0M | 107.0M | 177.0% | 181.6M | — | — | — |
| Equity | -7.3M | 43.5M | 133.6M | 8.0M | -57.1% | — | — | — | — |
| Op CF | -90.8M | -193.3M | -194.4M | -129.8M | — | -131.9M | — | — | — |
| Inv CF | -0.7M | -4.6M | -2.6M | -28.0K | — | — | — | — | — |
| Fin CF | 91.5M | 202.0M | 71.7M | 101.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INBX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INBX | Inhibrx Biosciences, Inc.(you) | $1.8B | 13 | Strong Sell |
| RXRX | Recursion Pharmaceuticals, Inc. | $1.8B | 12 | Strong Sell |
| TSHA | Taysha Gene Therapies, Inc. | $1.9B | 14 | Strong Sell |
| STOK | Stoke Therapeutics, Inc. | $2.0B | 13 | Strong Sell |
| KARD | Kardigan, Inc. | $1.9B | 11 | Strong Sell |
| BRVE | Braveheart Bio, Inc. | $1.9B | 11 | Strong Sell |
| KLRA | Kailera Therapeutics, Inc. | $2.1B | 11 | Strong Sell |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.1B | 11 | Strong Sell |
| ZBIO | Zenas BioPharma, Inc. | $2.0B | 15 | Strong Sell |
| NTLA | Intellia Therapeutics, Inc. | $1.8B | 7 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%